Sugi Predict

Sugi Predict / Compounds / SCHEMBL3689533

SCHEMBL3689533

SCHEMBL3689533

COC(=O)c1cc(Cl)c(C)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.46
▸ KMT2A Q03164 2/20 0.42
▸ ABL1 P00519 1/20 0.41
▸ SOS1 Q07889 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ CA12 O43570 4/20 0.39
▸ CA1 P00915 4/20 0.39
▸ CA2 P00918 4/20 0.39
▸ CA9 Q16790 4/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HPGD P15428 2/20 0.38
▸ CA7 P43166 2/20 0.37
▸ CA14 Q9ULX7 2/20 0.37
▸ LCK P06239 1/20 0.37
▸ FYN P06241 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18703677 0.86 GAA (0.46) GAAKMT2AABL1SOS1HTT
SCHEMBL31301254 0.85 GAA (0.49) GAAKMT2AABL1SOS1HTT
SCHEMBL8378560 0.85 GAA (0.49) GAAKMT2AABL1SOS1HTT
SCHEMBL16662001 0.85 GAA (0.51) GAAKMT2AABL1HTTMAPT
SCHEMBL18432612 0.85 KMT2A (0.46) GAAKMT2AABL1SOS1MAPT
SCHEMBL2538919 0.83 KMT2A (0.44) GAAKMT2ASOS1MAPTCA12
SCHEMBL19045818 0.83 GAA (0.50) GAAKMT2AABL1HTTMAPT
SCHEMBL7863946 0.83 GAA (0.50) GAAKMT2AABL1HTTMAPT
SCHEMBL31218239 0.81 GAA (0.45) GAAKMT2AABL1SOS1HTT
SCHEMBL19682919 0.81 GAA (0.57) GAAKMT2AHTTMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114040911-B As NAV1.8 2, 3-Dihydro-quinazoline Compounds as inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2024-10-22 — — CN disclosed
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 — — US disclosed
EP-3990436-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2022-05-04 — — EP disclosed
CN-114040911-A As NAV1.8 inhibitors of 2, 3-dihydroquinazoline compounds 葛兰素史密斯克莱知识产权发展有限公司 2022-02-11 — — CN disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 — — US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 — — US disclosed
WO-2020261114-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-30 — — WO disclosed
WO-2020261114-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-12-30 — — WO disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 — — US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 — — EP disclosed
WO-2008122014-A1 BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2008-10-09 — — WO disclosed
WO-2008122014-A1 BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2008-10-09 — — WO disclosed
US-20080242596-A1 BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2008-10-02 — — US disclosed
US-20080242596-A1 BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2008-10-02 — — US disclosed
US-20080242596-A1 BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2008-10-02 — — US disclosed
WO-2007140191-A2 GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE THERACOS, INC. (US) 2007-12-06 — — WO disclosed
WO-2007140191-A2 GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE THERACOS, INC. (US) 2007-12-06 — — WO disclosed
US-20070275907-A1 GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE SEED, BRIAN 2007-11-29 — — US disclosed
US-20070275907-A1 GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE SEED, BRIAN 2007-11-29 — — US disclosed
US-20070275907-A1 GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE SEED, BRIAN 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 GAA 2150/4885KMT2A 869/4885ABL1 2441/4885
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B GAA 2380/4885KMT2A 2375/4885ABL1 1261/4885
US-20070275907-A1 GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE SLC5A1, SLC5A2, SLC2A1 GAA 223/4885KMT2A 2818/4885ABL1 1273/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 GAA 2150/4885KMT2A 869/4885ABL1 2441/4885
US-20080242596-A1 BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE SLC5A2, SLC5A1, SLC2A1 GAA 146/4885KMT2A 2273/4885ABL1 1041/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B GAA 2949/4885KMT2A 1647/4885ABL1 2821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.